Clinical trials: Secondary Immune Deficiency
Aging, Hiv
2nd AC+: New Village Model
This study evaluates implementation of the Village Model to support older people living with HIV.
- Conditions
- Aging, Hiv, Loneliness, Social Isolation
- Trial name
- 2nd AC+ (NCT04323176)
- Testing
- Village Model implementation
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Human Immunodeficiency Virus
Secondary Distribution of HIV Self-tests: an Innovative Strategy for Promoting Partner Testing and Reducing HIV Risk
This cluster randomized trial will assess whether the provision of multiple oral-fluid based HIV self-test kits to HIV-negative women at high risk of acquiring HIV in western Kenya is an approach that promotes HIV testing among…
- Trial name
- NCT03135067
- Testing
- Provision of multiple self-tests
- Where
- Kenya
- Volunteers
- 2,102 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Primary Immunodeficiency (PID), Secondary Immunodeficiency (SID)
Assessment of Immunoglobulins (IgG) in a Long-term Non-interventional Study
This non-interventional, epidemiological study assesses long-term outcomes in subjects receiving immunoglobulins (IgG) for any treatment purpose, irrespective of the regimen prescribed by the treating physician, under routine…
- Conditions
- Primary Immunodeficiency (PID), Secondary Immunodeficiency (SID), Neurological Autoimmune Disease
- Trial name
- SIGNS (NCT01287689)
- Testing
- Immunoglobulin G (IgG)
- Where
- 7 sites in Germany
- Volunteers
- 685 people
- Sponsor
- Technische Universität Dresden
Covid19, Immune Deficiency
The Relationship Between Covid-19 Infection in Pediatric Patients and Secondary Lymphoid Organs
We aimed to find out whether the tonsils and nasal tissues of pediatric patients are the main factors that protects the children's immune system against COVID-19 infection.
- Conditions
- Covid19, Immune Deficiency, Tonsillitis, Tonsil Hypertrophy
- Trial name
- NCT04646525
- Testing
- Physical examination
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people
- Sponsor
- Selcuk University
HIV Infections
Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment
For treatment of human immunodeficiency virus type 1(HIV-1), publicly funded programmes tend to follow World Health Organization (WHO) guidelines to use a non-nucleoside reverse transcriptase inhibitor (NNRTI) combined with two…
- Trial name
- NCT02227238
- Testing
- DTG, LPV/RTV, Two NRTIs
- Where
- 59 sites in Argentina, Brazil and 11 more
- Volunteers
- 627 people
- Sponsor
- ViiV Healthcare
Neoplasm Metastasis
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors
- Trial name
- NCT04458259
- Testing
- PF-07265807, Sasanlimab, Axitinib
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 88 people
- Sponsor
- Pfizer
HIV Infection
ODYSSEY (PENTA 20)
A new anti-HIV medicine (Dolutegravir) combined with 2 currently used anti-HIV medicines is non-inferior to the standard combination of medicines used in terms of efficacy and better in terms of toxicity.
- Trial name
- NCT02259127
- Testing
- Dolutegravir, Standard of Care
- Where
- 28 sites in Germany, Portugal and 6 more
- Volunteers
- 792 people
- Sponsor
- PENTA Foundation
Acute Myeloid Leukemia/Myelodysplastic Syndrome, Multiple Myeloma (MM)
A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications
THINK (THerapeutic Immunotherapy with NKR-2) is a multinational (EU/US) open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 cells in seven refractory cancers…
- Trial name
- THINK (NCT03018405)
- Testing
- NKR-2 cells
- Where
- 5 sites in United States, Belgium
- Volunteers
- 146 people
- Sponsor
- Celyad Oncology SA
HIV Infection
Discontinuation of Primary and Secondary Prophylaxis for Opportunistic Infections in HIV-infected Patients
The purpose of this study is to compare the incidence of opportunistic infections between HIV-infected patients who continue and discontinue primary or secondary prophylaxis for opportunistic infections in whom receiving…
- Trial name
- NCT01392430
- Testing
- Discontinuation of prophylactic drugs i.e. co-trimoxazole, dapsone, fluconazole, itraconazole, azithromycin
- Where
- Thailand
- Volunteers
- 74 people
- Sponsor
- Chiang Mai University
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have…
- Conditions
- AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma
- Trial name
- NCT02595866
- Testing
- Antiretroviral Therapy, Biopsy, Biospecimen Collection
- Where
- 12 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Granulomatous Disease, Chronic
Use of Busulfan as Conditioning Agent for a Second Stem Cell Transplant
This protocol is designed for a single specific patient. It uses busulfan as a conditioning agent in a second stem cell transplant procedure for a patient with chronic granulomatous disease (CGD), a disorder in which a certain…
- Trial name
- NCT00092937
- Testing
- Busulfan
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
HIV-infection/Aids, Human Herpesvirus 4 Infections
Inflammation and Co-Infections in D²EFT
i2-D²EFT substudy is an observational cohort nested within the parent D²EFT study (NCT03017872). D²EFT goal is to compare the standard of care second-line antiretroviral therapy in people living with HIV whose first-line non…
- Conditions
- HIV-infection/Aids, Human Herpesvirus 4 Infections, Cytomegalovirus Infections, Human Herpesvirus 8 Infection
- Trial name
- i2-D²EFT (NCT04183738)
- Testing
- NRTIs, Darunavir, Ritonavir
- Sponsor
- Kirby Institute
HIV Infections, Cytopenias
A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine
To assess the safety and efficacy of subcutaneous sargramostim ( granulocyte-macrophage colony-stimulating factor; GM-CSF ) in increasing and maintaining the granulocyte count in HIV-infected children who have developed…
- Trial name
- NCT00002263
- Testing
- Zidovudine, Sargramostim
- Where
- United States
- Sponsor
- Sandoz
HIV Infections
A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP
This international, multi-centre, double-blind vaccine study is a three-arm prospective 1:1:1 randomisation comparing each of two experimental combination vaccine regimens i.e.
- Trial name
- PrEPVacc (NCT04066881)
- Testing
- Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48), Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48), Control PrEP:TDF/FTC once daily (weeks 0-26)
- Where
- Uganda
- Volunteers
- 1,512 people, healthy volunteers welcome
- Sponsor
- MRC/UVRI and LSHTM Uganda Research Unit
Secondary Immunodeficiencies (SID)
Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients
Retrospective, representative registry for quality assurance on diagnosis and therapy of secondary immunodeficiencies (SID) in patients with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM)
- Trial name
- QS-SID (NCT04172467)
- Testing
- non-interventional retrospective epidemiological observational study
- Where
- Germany
- Volunteers
- 1,086 people
- Sponsor
- AIO-Studien-gGmbH
Hiv, Chlamydia
Online HIV Prevention for Young Male Couples
Young gay, bisexual, and other men who have sex with men (YMSM) are the only risk group in which rates of new HIV infections are on the rise.
- Conditions
- Hiv, Chlamydia, Gonorrhea
- Trial name
- 2GETHER (NCT03284541)
- Testing
- 2GETHER, Existing Public Health Practice
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Primary or Secondary Immune Deficiency Including Immunosuppressive Therapy, Chemotherapy, HIV Infection
Performance of Clinical Metagenomics in Stool and Urine Samples for Unexplained Diseases Diagnostic and Emerging Diseases Surveillance in Immunocompromised Patients
The study is based on the hypothesis that the concomitant use of mNGS in non-invasive samples (stool, urine) could improve the rate of detected pathogens in immunodeficient patients compared with mNGS performed in an invasive…
- Trial name
- SENTINEL (NCT07603453)
- Testing
- Metagenomics
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Secondary Immune Deficiency
The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency
Patients with Myeloma or CLL with severe secondary hypogammaglobinemia and recurrent infections will be included in this study; for whom an IgSC treatment was prescribed.
- Trial name
- NCT03369301
- Testing
- Gammanorm, Other Subcutaneous Immunoglobulins
- Where
- 6 sites in France
- Volunteers
- 102 people
- Sponsor
- Octapharma
HIV Infections, ART
Evaluation of Secondary Distribution of HIV Self-screening Tests by Women With HIV
Many South African men do not visit clinics or get tested due to multiple real and perceived barriers. Nkangala District has significant gaps to identifying PLHIV who are not on ART, reaching their ART targets, especially in…
- Conditions
- HIV Infections, ART, HIV Seropositivity
- Trial name
- HIVSSSA (NCT05074251)
- Testing
- HIV self test, Counseling and referral for partner testing
- Where
- South Africa
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles